Functional evidence that the central renin-angiotensin system plays a role in the pressor response induced by central injection of carbachol

Brazilian Journal of Medical and Biological Research

Volumn 30, Issue 4, 1997, Pages 493-496

  Saad, W A ^a   Luiz, A C ^a   Camargo, L A A ^a   Silveira, J E N ^a   Foglia S ^a   Menani, J V ^a   Saad, William A ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

carbachol; central angiotensin; pressor response

Indexed keywords

ANGIOTENSIN; CARBACHOL; LOSARTAN; LOSARTAN POTASSIUM; RAMIPRIL;

ANIMAL EXPERIMENT; CHOLINERGIC SYSTEM; CONFERENCE PAPER; CONTROLLED STUDY; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; MALE; NONHUMAN; PRESSOR RESPONSE; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ANIMALIA;

EID: 0030958097     PISSN: 0100879X     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0100-879X1997000400010     Document Type: Conference Paper

References (20)

1. Huffman WE & Phillips MJ (1976). A pressor response to intraventricular injection of carbachol. Brain Research, 105: 157-162.
2. Huffman WE, Phillips MI, Schmid PG, Falcon J & Weet JF (1977). Antidiuretic hormone release and the pressor response to central angiotensin II and cholinergic stimulation. Neuropharmacology, 16: 463-472.
3. Imai Y, Abe K, Sasaki S, Minami N, Munakata M, Yumita S, Nobunaga T, Sekino H & Yoshinaga K (1989). Role of vasopressin in cardiovascular response to central cholinergic stimulation in rats. Hypertension, 13: 549-557.
4. Brody MJ & Johnson AK (1980). Role of the anteroventral third ventricle region in fluid and electrolyte balance, arterial pressure regulation and hypertension. In: Martini L & Ganong WF (Editors), Frontiers in Neuroendocrinology. Raven Press, New York, 249-292.
5. Menani JV, Saad WA, Camargo LAA, Renzi A, De Luca Jr LA & Colombari E (1990). The anteroventral third ventricle (AV3V) region is essential for pressor, dipsogenic and natriuretic responses to central carbachol. Neuroscience Letters, 113: 339-344.
6. Johnson AK & Loewy AD (1990). Circumventricular organs and their role in visceral functions. In: Loewy AD & Spyer K (Editors), Central Regulation of Autonomic Functions. Oxford University Press, New York, 247-267.
7. Freer RJ, Sutherland JC & Day AR (1980). Synthesis and pharmacology of a noncompetitive antagonist of angiotensin-induced contractions of vascular smooth muscle. Circulation Research, 46: 720-725.
8. Tabrizchi R & Pang CCY (1987). Are angiotensin receptors in vascular smooth muscles a homogenous population? European Journal of Pharmacology, 142: 359-366.
9. Trachte GJ & Peach MJ (1983). A potent noncompetitive angiotensin II antagonist induces only competitive inhibition of angiotensin II responses. Journal of Cardiovascular Pharmacology, 5: 1025-1033.
10. Colombari DSA, Saad WA, Camargo LAA, Renzi A, De Luca Jr LA, Colombari E & Menani JV (1992). AV3V lesion impairs responses induced by cholinergic activation of SFO in rats. American Journal of Physiology, 263: R1277-R1283.
11. Colombari E, Saad WA, Camargo LAA, Renzi A, De Luca Jr LA & Menani JV (1992). AV3V lesion suppresses the pressor, dipsogenic and natriuretic responses to cholinergic activation of the septal area in rats. Brain Research, 572: 172-175.
12. Haibara AS, Saad WA, Camargo LAA, Menani JV, Renzi A, De Luca Jr LA & Antunes-Rodrigues J (1992). Opiate activation suppresses the drinking, pressor and natriuretic responses induced by cholinergic stimulation of the medial septal area. Brain Research Bulletin, 28: 155-160.
13. Robin B, Antonaccio MJ & Horovitz ZP (1978). Captopril (SQ 14.225) (D-3-mercapto-2-methylpropranoyl-L-proline):a novel orally active inhibitor of angiotensin agent. Progress in Cardiovascular Disease, 21: 183-194.
14. Unger T, Ganten D, Lang RE & Scholkens BA (1985). Persistent tissue converting enzyme inhibition following chronic treatment with Hoe 498 and MK 401 in spontaneously hypertensive rats. Journal of Cardiovascular Pharmacology, 7: 36-41.
15. Dzau VJ (1988). Molecular and physiological aspects of tissue renin-angiotensin system: emphasis on cardiovascular control. Journal of Hypertension, 6: S7-S12.
16. Iwai N, Yamano Y, Chaki S, Konishi F, Bardhan S, Tibbetts C, Sasaki K, Hasegawa M, Matsuda Y & Inagami T (1991). Rat angiotensin II receptor: cDNA sequence and regulation of the gene expression. Biochemical and Biophysical Research Communications, 177: 299-304.
17. Karlberg BE, Lindistroem T, Rosenquist V & Oehamn KP (1987). Efficacy, tolerance and hormonal effects of a new oral angiotensin converting enzyme inhibitor, ramipril (HOE-498), in mild to moderate primary hypertension. American Journal of Cardiology, 59: 140D-149D.
18. Predel HG, Duesing R, Baecker A, Kipnowiski J & Kramer HJ (1987). Combined treatment of severe essential hypertension with the new angiotensin converting enzyme inhibitor ramipril. American Journal of Cardiology, 59:143D-148D.
19. Cunningham JT & Johnson AK (1989). Decreased norepinephrine in the ventral lamina terminalis region is associated with angiotensin II drinking response deficits following local 6-hydroxydopamine injections. Brain Research, 480: 65-71.
20. Bellin SI, Landas SK & Johnson AK (1988). Selective catecholamine depletion of structures along the ventral lamina terminalis: effects on experimentally-induced drinking and presser responses. Brain Research, 456: 9-16.